Zobrazeno 1 - 10
of 116
pro vyhledávání: '"recurrent high-grade glioma"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and c-Kit. T
Externí odkaz:
https://doaj.org/article/8c5f2ed1eb644a628b6da65075b7e4b7
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
Autor:
Zhuang Kang, Shan Li, Xun Kang, Jing Deng, Huarong Yang, Feng Chen, Jiandong Jiang, Jie Zhang, Wenbin Li
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 6, Pp 465-476 (2023)
Objective: This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation
Externí odkaz:
https://doaj.org/article/efee3ef542da48b0a556efcaceadc336
Autor:
Sean S. Mahase, Michelle Roytman, Diana Roth O'Brien, Jana Ivanidze, Theodore H. Schwartz, Susan C. Pannullo, Rohan Ramakrishna, Rajiv S. Magge, Nicholas Williams, Howard A. Fine, Gloria Chia‐Yi Chiang, Jonathan P. S. Knisely
Publikováno v:
Cancer Reports, Vol 6, Iss 7, Pp n/a-n/a (2023)
Abstract Background Clinical trials evaluating immune checkpoint inhibition (ICI) in recurrent high‐grade gliomas (rHGG) report 7%–20% 6‐month progression‐free survival (PFS), while re‐irradiation demonstrates 28%–39% 6‐month PFS. Aims
Externí odkaz:
https://doaj.org/article/f68f477da7f84ce68a99057c715f8650
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yun Guan, Ji Xiong, Mingyuan Pan, Wenyin Shi, Jing Li, Huaguang Zhu, Xiu Gong, Chao Li, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang, Enmin Wang, Xin Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for i
Externí odkaz:
https://doaj.org/article/821390da4de5404390532f51986844f8
Autor:
Donatella Arpa, Elisabetta Parisi, Giulia Ghigi, Annalisa Cortesi, Pasquale Longobardi, Patrizia Cenni, Martina Pieri, Luca Tontini, Elisa Neri, Simona Micheletti, Francesca Ghetti, Manuela Monti, Flavia Foca, Anna Tesei, Chiara Arienti, Anna Sarnelli, Giovanni Martinelli, Antonio Romeo
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe presence of hypoxic cells in high-grade glioma (HGG) is one of major reasons for failure of local tumour control with radiotherapy (RT). The use of hyperbaric oxygen therapy (HBO) could help to overcome the problem of oxygen deficiency
Externí odkaz:
https://doaj.org/article/e49d14be67fc4464bce2fc1ecba73559
Autor:
Yun Guan, Jing Li, Xiu Gong, Huaguang Zhu, Chao Li, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang, Enmin Wang, Ying Liu, Xin Wang
Publikováno v:
Brain Sciences, Vol 12, Iss 4, p 471 (2022)
(1) Background: Hypofractionated stereotactic radiotherapy (HSRT) and anti-vascular endothelial growth factor (VEGF) antibodies have been reported to have a promising survival benefit in recent studies. Anlotinib is a new oral VEGF receptor inhibitor
Externí odkaz:
https://doaj.org/article/0e5ee921d0f84d799027542208bf0bdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Melike Mut, Kader Karli Oguz, Sadettin Kilickap, Sezin Yuce Sari, Aysenur Elmali, Mustafa Erman, Neyran Kertmen, Figen Soylemezoglu, Gozde Yazici, Burak Yasin Aktas, Faruk Zorlu
Publikováno v:
Cureus
Background Radiotherapy (RT) with immune checkpoint inhibitors (ICI) has yielded good responses in many cancers. We aimed to report the results of combined fractionated stereotactic radiotherapy (FSRT) and ICI in patients with recurrent high-grade gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f0d811a4968909c9574c7761b12d1a
https://pubmed.ncbi.nlm.nih.gov/34327080
https://pubmed.ncbi.nlm.nih.gov/34327080